Immune-related genes can accurately predict survival in bladder cancer: a retrospective study via two independent immunotherapy cohorts.

ABSTRACT:

Background

Bladder cancer (BLCA) is an aggressive malignancy characterized by high rate of recurrence. Its steadily increasing incidence and prevalence have made it one of the most prevalent urogenital tract tumors worldwide. Although immunotherapy serves as a first-line treatment for BLCA, patient prognosis shows significant heterogeneity. Risk stratification through immunotherapy risk scoring could substantially improve prognostic predictions. However, current studies examining the use of immune treatment risk scores to predict the prognosis of immunotherapy across various patients with BLCA remain in its early stages. This research aims to identify immune-related genes as potential biomarkers for BLCA immunotherapy guidelines.

Methods

To fill this gap, we used two indepen

SUBMITTER: Shen J 

PROVIDER: S-EPMC12271934 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature